Angel Seafood $AS1 $AS1.AX is the largest oyster producer in Coffin Bay, making news for all the wrong reasons. A real microcap seeking to build scale, is now the time to swim against the tide? 🦪

Let’s take a deep dive. 👇 Image
1. Investment thesis: Fast Grower.
✅Strong market for oysters
✅Revenue ramping up
✅CAPEX pulling back
✅Biomass in place for scaling
✅Skin in the game
🚨Food poisoning / sales suspension
2. Recently I looked at East 33 $E33 as an oyster play – sorry folks, it was a ruse!

That was my competitor research on Angel, which has taken a lot longer to get my head around due to the lack of information available.
3. The global market for oyster production and exports have been growing rapidly. Oysters are very efficient (near zero food inputs required). Australia is a small but increasing player in this space. Image
4. Sydney rock oysters ($E33) are substantially different to Pacific oysters ($AS1). Sydney’s take longer to mature, but have more appeal in the luxury and export markets. Image
5. The unit economics for Pacific Oysters are much better.

Lower inventories due to time of maturity, able to be grown in more locations all year round, and generally a lower cost of production with lower price point. Image
6. Angel Seafood are the largest producers of Pacific Oysters in Australia.

They are a microcap (MC=$20m) with a short history and large ambitions, led by a founder-CEO with skin in the game. CFO is pretty impressive to listen too. Image
7. Angel operate out of Coffin Bay in South Australia, with an integrated (From larvae to your lunchbox? From spat to snack?) production capacity across three bays on the Eyre Peninsula. Image
8. One may be surprised, but they’re actually profitable.

Unlike some other micro-aquaculture stocks with terrible unit economics that may never be profitable ( $SFG $MCA 👀), these folks are already in the black on the P&L but not cash flow. Image
9. Growth has been lumpy.

This is partly driven by seasonal factors (e.g. bigger Sep-Dec quarter with Christmas sales. But on an annualised basis, you can see the growth in biomass and revenue. And they may just now be ready to ramp with their biomass haul. Image
10. Angel have a three pillared approach to growth:

🎯Roll up the marine licenses
🎯Productivity improvements
🎯Premiumisation and pricing power Image
11. The supply chain for Pacific Oysters is fragmented and relatively complex.

Production is fragmented, there are multiple distribution channels, limited value creation and a high number of intermediaries. Image
12. Coffin Bay has over 350 license holders for Oysters, and Angel represents ~25% of production.

Economies of scale and profit make them the go-to for those wanting to get-out. This could be handy during the current gastro-crisis if there are distressed license holders. Image
13. Flip farms will improve productivity, while Summer Oysters will enable all-year-round production and sales of their Pacific Oysters. Image
14. Being able to produce year-round low-cost oysters is driving the growth in the oyster market.

This will expand the retail outlets ( $WOW $COL ), which currently are only 2-5% but have potential for much more. They tend to prefer the smaller/cheaper oysters too. Image
15. Their direct-to-consumer Halo Club is another way of capturing more of the oyster value.

To be frank, not sure many folks will sign up for a subscription for $100 of 3 doz oysters per month.🤷 Image
16. The strategy is to get to 20m, and they have the licenses, infrastructure and biomass to get there in the next couple of years.

You can hear more about this on @CMicrocaps 👇

17. Biosecurity risks can be quite severe in any primary industry, but particularly aquaculture. Just last week PIRSA banned the sale of Coffin Bay oysters as it was linked to food poisoning – doesn’t affect the oysters.

abc.net.au/news/2021-11-1…
18. With only 7-10 days of inventory in the supply chain, I think this recall will be less damaging (~$250k of revenue) than the movement in the share price (from 16c to 13c, or $4.5m).

Though if it drags on, or they run out of cash, then the market may be right.
19. @ElephantCapita2 has provided some technical analysis showing we’re near the base.

Share price has now approached NTA of 11.4c as of June 2021.

Previous cap raise was at 17c including insider participation. Image
20. Liquidity is strong for Angel with around $4m of headroom.

This PIRSA matter shouldn’t impact their long term survivability. It may even shake out some of those 351 license holders at good valuations.🤞
(Not nice really to cheer on distressed sales, sorry) Image
21. Risks are real 🚨
This is a microcap in the midst of a food poisoning scandal that could lead to brand deterioration, shifting preferences, etc. While sales should be back on from 29th of November, no guarantees.
theguardian.com/australia-news…
22. Skin in the game.

CEO Isaac Halman has ~15% of the company, other directors in total around ~8%, and two major shareholders (Thorney = long term value investor) with around ~13% each. Thinly traded, tightly held. Image
23. Overall, I like the sort of investments where previous shareholders pay the CAPEX and I get to reap the rewards of growth. The market dynamics look good, and so does the business strategy. Execution to be proven.

It’s high risk so only a small allocation.
If you enjoyed this, bash the like / retweet / follow buttons.

A deep dive per week is my commitment to FinTwit - failing, sorry!

Questions and feedback always welcome. DYOR.

Disclaimer, I have a small position in $AS1
If they get to 20m target in 3 years as per Simba's comments, and assuming no additional efficiencies, then..

Rev: Up from ~$6 to $15m
Ebitda: Up from ~$1.5m to $5.5m
NPAT: Up from ~$1.2m to $4m
PE: Down from 16.6 (CY20) or to 5 (CY23f). Image

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Value Downunder

Value Downunder Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DownunderValue

3 Nov
East 33 $E33 $E33.AX is a premium Sydney Rock Oyster company that recently IPO’d. Substantive performance rights for management with a colourful history will likely drive a debt-fueled acquisition binge and short term shareholder returns.

Let’s take a deep dive. 👇 Image
1. Investment thesis: Special situation.
✅Fast top-line growth driven by acquisitions.
✅Strong market conditions.
🚩Performance incentives for EBIT and share price growth.
🚩Debt financed.
🚩History of poor management.
2. East 33 farms native Sydney Rock Oysters – a premium product.

Vertically integrated, they have an export approved facility, export certificate, 195ha of farming licenses, and a nursery. Image
Read 25 tweets
29 Oct
Costa Group Holdings $CGC $CGC.AX is Australia’s largest grower, packer and marketer of fresh fruit and vegetables. If you like your berries, mushrooms, tomatoes, avocados and citrus, maybe you’ll like the taste of Costa Group.

Let’s take a deep dive. 👇 Image
1. Investment thesis:
✅Stalwart.
✅Market leading position in multiple growing consumer staples lines.
✅International expansion.
✅Generating decent operating free cash flow.
✅Trading at 52 week lows.
🚩CAPEX requirements
🚩Margins & growth rates.
2. Costa’s has grown over the years by modernising fruit and veg growing – bringing new varieties, 52-week availability to supermarkets, economies of scale, and locations near to major urban centres. Image
Read 22 tweets
29 Sep
Wake up to find out Europe is in a gas crisis, Barnaby Joyce is worried about burping cows, and now you find your portfolio is underweight #seaweed ? Me too.

Let's take a look at 'Australian Seaweed As A Megatrend' 👇
1. Investment Thesis: Early stage investing in seaweed as a nascent industry with significant growth potential due to multiple mega trends (climate change, organic fertilizers, food security, and biopharma); moving from research into commercialisation.
2. What is seaweed?

Seaweed biomass can be used for an array of possible uses including food, animal feed, high-value pharmaceutical/ industrial compounds, biofuels, and fertilisers. It's grown in water, and has environmental benefits.
Read 24 tweets
23 Sep
Rubicon Water Limited $RWL $RWL.AX is an irrigation efficiency hardware and software company. They've built out from Australia into US, Europe and recently China and India - big markets. After successfully IPO'ing this month, they're up 75%.

Here's why I'm not chasing 👇 Image
1. Investment Thesis: Unknown
❌Stalwart
❌Slow Grower
❌Fast Grower
❌Cyclical
❌Asset Play
❌Turnaround
✅Story Stock

"Water water everywhere, but not a drop to drink", Coleridge poem. Image
2. Story starts at food security.

With a growing population and increasing wealth, we simply have a need for more food production. This trend is not going to stabilise any time soon. Image
Read 23 tweets
16 Sep
Genex $GNX $GNX.AX is a renewable energy developer with a focus on firming through pumped hydro and batteries. After 6yrs in the sin bin for epic delays, what's changed?

@ElephantCapita2 will also share his technical analysis to answer 'why now?'

Let’s take a deep dive.👇
1. Investment thesis: Turnaround / Asset play.

A high CAPEX company, in a growing sector, potential takeover target, progressed through multiple de-risking events, but due to failures since IPO in 2015 its priced markedly below fair value.

Potential to become a stalwart?🤷
2. Growing demand for renewables.

There’s a long tailwind of renewable energy growth, both as total consumption increases and renewables replace fossils. Wind, solar and other (inc. bioenergy) are growing, and Genex is positioning itself in that super fast growing space.
Read 25 tweets
10 Sep
Avita Medical Inc. $AVH $AVH.AX is best known for its product ReCell $RCEL – spray on skin for burns victims. After a long history of innovation, commercial success has evaded this once-darling. Is this time different?

Let’s take a deep dive on 3 key metrics to watch.👇 Image
1. Investment thesis: Fast grower / turnaround.

Innovative product with clear use case, competition falling way, optionality on new applications, top-line growth as adoption improves. Questionable management. Image
2. History in a nutshell. Founded as ‘Clinical Cell Culture’ in 1993 by Prof. Fiona wood who developed the tech with Marie Stone. First big test for ReCell was after the 2002 Bali Bombings treating the burn victims. renamed Avita in 2008. Image
Read 23 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(